Do the pros of neoadjuvant chemotherapy in sarcoma outweigh the cons?
Neoadjuvant chemotherapy is on course to become standard treatment for selected high-risk soft tissue sarcomas but effects in low-risk disease are unclear
Progress is being made in treating sarcomas in adolescents and young people
Despite age-specific difficulties, increased understanding of sarcoma biology is leading the way to the development of new treatment strategies